PD-1/PD-L1抑制剂在未分化甲状腺癌中的研究进展  

Research progress of PD-1/PD-L1 inhibitors in anaplastic thyroid cancer

作　　者：鲍欣[1] 刘爽(综述)[1] 张弘(审校)[1] Bao Xin;Liu Shuang;Zhang Hong(Department of Thyroid Surgery, the Second Hospital of Jilin University, Jiling Province,Changchun 130041 China)

机构地区：[1]吉林大学第二医院甲状腺外科,长春130041

出　　处：《疑难病杂志》2022年第6期656-659,664,共5页Chinese Journal of Difficult and Complicated Cases

基　　金：吉林省卫生健康科技能力提升项目(2021JC017)。

摘　　要：程序性死亡受体1(PD-1)和程序性死亡配体1(PD-L1)是重要的免疫检查点分子,参与了肿瘤免疫的负性调节,促进肿瘤的发生、发展。PD-1/PD-L1抑制剂已经在黑色素瘤、肺癌、肝癌等多种肿瘤中显现出显著的临床疗效。文章主要对PD-1/PD-L1的结构、在肿瘤微环境中的作用机制以及PD-1/PD-L1免疫检查点抑制剂在未分化甲状腺癌中的相关研究进展进行综述。Programmed death receptor 1(PD-1)and programmed death ligand 1(PD-L1)are important immune checkpoint molecules,which are involved in the negative regulation of tumor immunity and promote the occurrence and development of tumors.PD-1/PD-L1 inhibitors have shown significant clinical efficacy in melanoma,lung cancer,liver cancer and other tumors.This article mainly reviews the structure and mechanism of PD-1/PD-L1 in the tumor microenvironment,and the related research progress of PD-1/PD-L1 immune checkpoint inhibitors in anaplastic thyroid cancer.

关 键 词：未分化甲状腺癌 程序性死亡受体1 程序性死亡配体1 免疫治疗 免疫检查点抑制剂 

分 类 号：R736.1[医药卫生—肿瘤]